TRACON announces top-line results from Phase 2 trial
SAN DIEGO—TRACON Pharmaceuticals recently reported top-line results from a randomized Phase 2 clinical trial of TRC105 in recurrent glioblastoma (GBM) funded and conducted by the Clinical Therapy Evaluation Program of the National Cancer Institute. TRC105 combined with Avastin (bevacizumab) was compared to single-agent Avastin in 101 patients with recurrent GBM following chemoradiation. The trial was designed to detect a three-month improvement in progression-free survival (PFS), the primary endpoint, from the expected value of 3.45 months with single-agent Avastin. Top-line data indicate that the combination of TRC105 and Avastin did not improve median PFS vs. single-agent Avastin in recurrent GBM patients, although the combination was associated with a non-significant increase in overall survival. Detailed data and the associated correlative analyses are expected to be presented at an oncology conference later this year.